Stock XBIT XBIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

News XBiotech Inc.

Equities

XBIT

CA98400H1029

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
8.49 USD +5.86% Intraday chart for XBiotech Inc. +7.88% +112.25%
03-15 XBiotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
01-04 XBiotech Inc. to Begin Constructing New R&D Facility on Its 48-Acre Campus CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
XBiotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
GL
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
GL
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
AQ
XBiotech Inc. to Begin Constructing New R&D Facility on Its 48-Acre Campus
CI
XBiotech Inc. announced that it expects to receive $10 million in funding
CI
Dr. Alan Kivitz to Chair XBiotech s Natrunix Program in Rheumatoid Arthritis
AQ
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
GL
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
AQ
Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis
CI
XBiotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
GL
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
AQ
Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke
CI
XBiotech Inc.(NasdaqGS:XBIT) dropped from S&P Global BMI Index
CI
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
GL
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
AQ
Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
CI
XBiotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis Clinical Trial
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XBIT Stock
  4. News XBiotech Inc.